CODE France Launch Event at the 13th Biennale Monégasque de Cancérologie in Monaco, Report Published in French and English

Read More

The Collaboration for Oncology Data in Europe (CODE) and the Oncology Data Network (ODN), was officially launched in France on the 1st February 2018. The CODE launch event took place during the biennial cancer congress in Monaco. The congress attracts more than 1,300 professionals working in oncology including representatives from hospitals, cancer care centres, clinics and UNICANCER.

Keynote speaker, Professor Xavier Pivot, Director General of the Paul Strauss Centre in Strasbourg and Administrator of the Alsace Regional Cancer Institute, shared his vision on the clinical impact of data analysis.

The launch event was chaired by Professor Blay, a member of CODE’s international Clinical and Analytical Steering Committee (CASC). He was joined by Prof Gilles Calais, oncologist and radiotherapist at the Academic Hospital of Tours, Prof Samuel Limat, Professor of Clinical and Therapeutic Pharmacy and Dr Ashley Woolmore, Lead for the CODE initiative.

During the event there was a panel discussion on how the use of real-world data can transform patient care and help address the challenges of financial sustainability.

“The CODE initiative is of strategic importance and has the particular benefit of not just providing insights in France but also enabling us to compare ourselves with other countries, and this will be an important point in the years to come,” said Prof Blay.


Please click here for a full report of the event in French

Please click here for a full report of the event in English


For more information about joining the Oncology Data Network in France, please contact CODE Country Lead, Claire Lamotte at

CODE to be formally launched in the UK at the Oncology Forum 2018 in Liverpool

Read More

The Collaboration for Oncology Data in Europe (CODE) is being formally launched in the UK at the Oncology Forum in Liverpool from 14th to 15th June 2018.

The CODE team will be exhibiting at the event, attending the conference dinner and engaging with a number of groups through a range of short presentations at the Forum’s fringe meetings. We are excited to be sponsoring such an important event in the UK Oncology landscape.

If you would like to meet with the CODE team during the event, please get in touch with us by emailing

Supporting the journey to value-based healthcare: Winner announced for the VBHC Prize 2018

Read More

Following CODE’s sponsorship of the Value-Based Healthcare Prize 2018, members of the CODE team attended the awards ceremony in Nijkerk in the Netherlands on Thursday 26 April 2018. It was an honour to see Harvard University Professor Michael Porter, PHD, present the VBHC Award to The Netherlands Heart Network – huge congratulations on your win!

The CODE team would also like to congratulate Maxima Medical Centre, Cancer Treatment Centre in the Netherlands, who won the ‘Cost-effectiveness’ award.

Many congratulations to all the other winners on the day – it was great to celebrate all of the amazing work in the area of VBHC.

CODE officially launched in Germany at the German Cancer Congress 2018, event report published

Read More

On Thursday 22nd February 2018, the Collaboration for Oncology Data in Europe (CODE) was formally launched in Germany at the German Cancer Congress 2018 in Berlin. The event was entitled “Access to real-world cancer data: challenges and opportunities to improve patient care and financial sustainability across Europe.”

Keynote speaker Professor Frank Griesinger, Director of the Department of Haematology and Oncology at Pius-Hospital Oldenburg, provided a clinical perspective on the importance of having access to data to inform treatment decisions and the challenges that are faced by oncologists in Germany today. He stressed that “real-world data is very important and helpful because it is more representative of a broad spectrum of patients”.

Dr Ashley Woolmore, CODE Lead, outlined the mission for this project and said, “CODE aims to create an efficient, pragmatic way to gain powerful insight that can help improve access to care and to be a catalyst for further clinical research”.

The event also saw active engagement between the event participants and the panellists:

  • Professor Christian Burke (Medical Director at University Hospital Ulm)
  • Professor Dirk Arnold (Head of Department Oncology in the Section of Haematology & Palliative Care at Asklepios Klinik Altona)
  • Tino Sorge (Member of Bundestag and Health Committee; Rapporteur for eHealth and Health Economy at Conservative Parliamentary Group)
  • Professor Herbert Rebscher (Managing Director of Institute for Health Economics and Healthcare Research; former CEO of DAK)

Please click here for a full report of the event in English.

Please click here for a full report of the event in German.

CODE to be formally launched in Germany at the Deutscher Krebskongress 2018 in Berlin

Read More

The Collaboration for Oncology Data in Europe (CODE) is being formally launched in Germany at the 33rd Deutscher Krebskongress in Berlin from 21st to 24th February 2018.

The launch event, titled “Access to real-world cancer data: challenges and opportunities to improve patient care and financial sustainability across Europe“, will be held on 22nd February 2018 from 18:00 to 20:00 pm at CityCube Berlin. Attendance is by invitation only.

If you would like to meet with the CODE team during the Congress, please get in touch with us by emailing

The CODE Information Access and Publication Policy: anticipating broader access to information generated by the Oncology Data Network

Read More

A broad range of organisations are involved in clinical practice and policy development around cancer care. To help achieve our shared goals of enhancing patient care and helping address the challenges of financial sustainability, it is vital to ensure these stakeholders have access to information on the use of anti-cancer medicines in cancer treatment. Anticipating this important need, the members of CODE have developed an Information Access and Publication Policy.

Treatment centres that join the Oncology Data Network (ODN) will get access to up-to-date information at no cost, enabling them to compare their own site-level data with aggregated, non-identifiable information at a regional or country level across the ODN.

In addition, a wide range of other organisations will be able to request access to information based on non-identifiable aggregated data at a regional or country level which will ensure that data privacy of patient, treatment centre and clinicians are maintained. This information will provide valuable snapshots of the use of anti-cancer medicines. Standardised reports will be made available via a secure analytical portal. In addition, organisations will be able to apply for customised analyses.

This Policy is expected to apply to interested groups such as clinicians who are not yet part of the ODN, patient organisations, academic research organisations, scientific societies and professional bodies, national or European non-academic, non-governmental organisations and national and European Governmental agencies concerned with cancer care or cancer policy.

CODE’s Clinical and Analytical Steering Committee consisting of leading clinicians from across Europe will oversee the review of all applications to ensure clear and transparent governance.

It is envisaged that these resources will be available in 2019 once the Oncology Data Network has grown to a sufficient scale to enable meaningful analyses to be generated.

To learn more please contact us.

CODE officially launched at ESMO, event report published

Read More

On Sunday September 10th 2017, the Collaboration for Oncology Data in Europe was formally launched at the European Society for Medical Oncology Congress in a private event chaired by David Kerr, Professor of Cancer Medicine at University of Oxford.

Our keynote speaker Robert Madelin, Chairman of FIPRA and former European Commission’s Director General for Health & Consumer Policy and Communication Networks, Content & Technology, explored the linkages of data, health and innovation. He shared how, in this view, data underpins the EU health debates we need and posed the question of building trust for innovative care with a collaborative approach.

Dr Ashley Woolmore who is leading the CODE initiative then set out our vision for this project which was described by one participant as “perhaps the highlight of the ESMO meeting. I really did feel that we could change public health in a fundamental manner…”

In the panel session that followed, we were joined by Winald Gerritsen, Professor of Tumour Immunotherapy at Raboud University and Richard Bergstrom, Head of Pharma, SICPA and former Director General of EFPIA. There was great interest from the audience, particularly around how an initiative such as CODE could contribute to improving patient care.

Please click here for a full report of the event.

CODE: Informing patient care, enabling the independent development of flexible payment agreements, realising financial sustainability goals

Read More

There are three million new cases of cancer in Europe every year [1] . As a society, we know we need more effective anti-cancer medicines, with fewer side-effects, to offer better outcomes for those living with cancer.

Biopharmaceutical companies are committed to finding ways to fulfil that need and have invested heavily in the research and development of innovative therapies. As a result of that commitment, the number of effective anti-cancer medicines available for patients is growing substantially.

This success also heralds a shift in the way anti-cancer medicines are used. As people live with cancer for longer, there is a rise in the number of patients receiving sequential anti-cancer medicines, including combination therapies, increasingly tailored to meet the specific profile of an individual patient.

As Biopharmaceutical Members of the Collaboration for Oncology Data in Europe (CODE) [2] ,we believe that not enough is known today about how anti-cancer medicines are actually used in real-world clinical practice. Up to date, reliable information is vital. It not only informs patient care, but may also facilitate the independent development of more flexible payment agreements between payers and Biopharmaceutial companies that help address the challenge of financial sustainability. Such agreements may also better reflect the value of anti-cancer medicines in terms of their clinical benefit to patients, thereby helping to mitigate payers’ and providers’ financial risks.

Driven by these imperatives, CODE is supporting the creation of the Oncology Data Network (ODN). The ODN has been designed to collate anti-cancer medicine usage data for all types of cancer, all patients, and all treatment centres in Europe that wish to join. We believe this initiative is a source of valuable information to the oncology community in treating patients, and could provide an important contribution to our independent development of new kinds of flexible agreements based on real world usage of innovative anti-cancer medicines.

Our membership of CODE is a demonstration of our commitment to working with key stakeholders in healthcare systems to encourage the provision of timely information that can inform patient care and proactively address the issue of financial sustainability confronting the oncology community. As the Biopharmaceutical members of CODE, acting independently of one another, we each intend to propose new flexible payment models to help address the financial considerations associated with the use of anti-cancer medicines.

We all share an enduring commitment to research and innovation with the goal of making a significant contribution to the lives of people living with cancer. Together, through our support for the ODN, we are taking a proactive step towards ensuring the long-term financial sustainability of innovative anti-cancer medicines, whilst also providing healthcare systems across Europe with information that informs patient care.

[1] World Health Organization (WHO) Europe Region, Cancer, data and statistics (

[1] The Biopharmaceutical Members of CODE are: AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co, Merck and Pfizer

We are attending ESMO 2017 Congress, 8-12 September, Madrid, Spain

Read More

Visit our Collaboration for Oncology Data in Europe (CODE) Booth (#216) to see how we are focused on collating comprehensive, near real-time data on how anti-cancer medicines are actually used, for which patients, and in which combinations and sequences, across Europe.

You can also learn about how CODE is supporting the building of the large-scale Oncology Data Network, a platform that is enabling the aggregation of data on anti-cancer medicine usage for all forms of cancer, in all patients and for all treatment centres across Europe who wish to join. The data collated will enable the oncology community to derive greater value from anti-cancer medicines for patient benefit.

If you would like to arrange a meeting with one of our team or are interested in joining the Oncology Data Network please contact Natalie at

The Collaboration for Oncology Data in Europe (CODE) establishes Clinical and Analytical Steering Committee

Read More

Group of leading clinicians will provide clinical and analytical advice and guidance to support the development of the Oncology Data Network

A key part of CODE’s governance structure is the Clinical and Analytical Steering Committee (CASC). This group of leading clinicians from across the medical oncology community in Europe held its inaugural meeting on 15th May 2017. The CASC is chaired by Professor David Kerr, Head of Oncology at the University of Oxford. The CASC members have committed to playing an important role in shaping CODE’s work and the Oncology Data Network (ODN).

The CASC’s purpose is to identify ways in which the information generated via the Oncology Data Network (ODN) can be put to greater use and effect by the oncology community. The CASC will provide advice and guidance to CODE on an agreed range of clinical and analytical issues. It will play an important role in helping deliver the initiative’s goals to generate greater insights into patient care.

Commenting on the establishment of the CASC, Professor David Kerr said: “The ongoing growth of new anti-cancer medicines offers significant potential to improve treatment for cancer patients, but brings with it increasing treatment complexity and financial impact to the health care system. With the support from the Collaboration and the newly-established CASC, the ODN will provide much-needed timely information to help navigate this increasing complexity and ultimately deliver better care for patients.”

Dr Ashley Woolmore, Head of European Data and Evidence and Vice President at QuintilesIMS, who is leading the CODE initiative added: “the formation of the CASC and contribution of leading oncologists from around Europe to our work, marks an important step for CODE. We are looking forward to working closely with CASC members to help realise the potential of this initiative over the coming years.”

The members of the CASC are:

Professor David Kerr, University of Oxford, England (Chair)

Professor Dirk Arnold, Asklepios Klinik Altona, Germany

Professor Jean-Yves Blay, Centre Leon Berard, France

Professor Christian Buske, University of Ulm, Germany

Professor Alfredo Carrato, Institution Ramon y Cajal University Hospital, Spain

Professor Winald Gerritsen MD PHD, Radbound University Medical Centre, Netherlands

Professor Marc Peeters, University of Antwerp, Belgium

For detailed biographies of the CASC members, please click here. IQVIA is responsible for selection of, contracting and coordinating with members of the CASC. For more information about the scope of the CASC’s role, click here